Sugi Predict

Sugi Predict / Compounds / Chalcone

Chalcone

Chalcone

SCHEMBL570745

O=C(C=Cc1ccccc1)c1ccccc1.O=c1ccc2ccccc2o1

nearest known ligand 0.61

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1B1 Q16678 7/20 0.61
▸ MAOB P27338 4/20 0.61
▸ MAPT P10636 4/20 0.61
▸ LMNA P02545 2/20 0.61
▸ PLIN1 O60240 1/20 0.61
▸ BCHE P06276 1/20 0.61
▸ TNFRSF1A P19438 1/20 0.61
▸ ACHE P22303 1/20 0.61
▸ RECQL P46063 1/20 0.61
▸ PLIN5 Q00G26 1/20 0.61
▸ ABHD5 Q8WTS1 1/20 0.61
▸ CA12 O43570 3/20 0.56
▸ CA9 Q16790 3/20 0.56
▸ TDP1 Q9NUW8 2/20 0.56
▸ CA1 P00915 1/20 0.56
▸ CA2 P00918 1/20 0.56
▸ CA3 P07451 1/20 0.56
▸ CA4 P22748 1/20 0.56
▸ CA6 P23280 1/20 0.56
▸ CA5A P35218 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Chalcone SCHEMBL570744 1.00 CYP1B1 (0.61) CYP1B1MAOBMAPTLMNAPLIN1
Cinnamic Acid SCHEMBL4394045 0.87 CA9 (0.61) CYP1B1MAPTLMNAPLIN1ACHE
Cinnamic Acid SCHEMBL4394043 0.87 CA9 (0.61) CYP1B1MAPTLMNAPLIN1ACHE
(Z)-1,2-Diphenylethene SCHEMBL28022680 0.83 CA12 (0.74) MAOBMAPTLMNAACHECA12
Chalcone SCHEMBL27933279 0.81 CYP1B1 (0.61) CYP1B1MAOBMAPTLMNAPLIN1
Chalcone SCHEMBL27913991 0.80 CYP1B1 (0.88) CYP1B1MAOBMAPTLMNAPLIN1
Benzophenone SCHEMBL27755446 0.79 CA12 (0.71) MAOBLMNAACHECA12CA9
Coumarin SCHEMBL1090505 0.78 CA12 (0.83) MAOBLMNAACHECA12CA9
Coumarin SCHEMBL25431834 0.78 CA12 (0.91) MAOBMAPTLMNABCHEACHE
Chalcone SCHEMBL27581 0.78 CYP1B1 (1.00) CYP1B1MAOBMAPTLMNAPLIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108610319-A One kind is for detecting Al3+Chalcone Coumarins fluorescence probe synthesis and application 福建医科大学 2018-10-02 — — CN claimed
US-11950594-B2 Methods and compositions for inhibiting formation of biofilms INSTITUTE OF MICROBIOLOGY, CHINESE ACADEMY OF SCIENCES (CN) 2024-04-09 — — US disclosed
CN-116731030-A Synthesis method and antitumor application of several furopyrimidine-ibuprofen hybrid derivatives 湖北医药学院 2023-09-12 — — CN disclosed
US-20220167614-A1 METHODS AND COMPOSITIONS FOR INHIBITING FORMATION OF BIOFILMS INSTITUTE OF MICROBIOLOGY, CHINESE ACADEMY OF SCIENCES (CN) 2022-06-02 — — US disclosed
CN-113512074-A (E) -4-methyl-7-hydroxy-8- (3- (ferrocenyl) acryloyl) coumarin, and preparation method and application thereof 河南中烟工业有限责任公司 2021-10-19 — — CN disclosed
CN-109988560-B Novel coumarin derivative hydrazine fluorescent probe 济南大学 2020-09-29 — — CN disclosed
CN-108610319-A One kind is for detecting Al3+Chalcone Coumarins fluorescence probe synthesis and application 福建医科大学 2018-10-02 — — CN disclosed
CN-108610319-A One kind is for detecting Al3+Chalcone Coumarins fluorescence probe synthesis and application 福建医科大学 2018-10-02 — — CN disclosed
CN-106317030-A 4-indolyl coumarin derivative, and preparing method and application thereof 国家烟草质量监督检验中心 2017-01-11 — — CN disclosed
US-8815940-B2 Coumarin-chalcones as anticancer agents COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2014-08-26 — — US disclosed
US-20130210909-A1 COUMARIN-CHALCONES AS ANTICANCER AGENTS COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2013-08-15 — — US disclosed
EP-2601183-A1 COUMARIN-CHALCONES AS ANTICANCER AGENTS Council Of Scientific & Industrial Research (IN) 2013-06-12 — — EP disclosed
CN-102516235-A Dibenzothiophene chalcone containing coumarin skeleton and synthesis method and application thereof UNIV SOUTH CHINA NORMAL 2012-06-27 — — CN disclosed
WO-2012017454-A1 COUMARIN-CHALCONES AS ANTICANCER AGENTS COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2012-02-09 — — WO disclosed
US-6767916-B2 1-(4-METHYL-7-(3-METHYLBUT-2-ENYLOXY)COUMARIN-8-YL)-3-(PYRIDIN E-3-YL)- PROPEN-1-ONE FOR EXAMPLE; ANTIPROLIFERATIVE AGENT; TUMOR, CANCER TREATMENT INDENA S.P.A. (IT) 2004-07-27 — — US disclosed
CN-1142927-C Chalcone coumarins Ӣ���ɹɷ����޹�˾ 2004-03-24 — — CN disclosed
CN-1142927-C Chalcone coumarins Ӣ���ɹɷ����޹�˾ 2004-03-24 — — CN disclosed
US-20020161036-A1 1-(4-methyl-7-(3-methylbut-2-enyloxy)coumarin-8-yl)-3-(pyridin e-3-yl)- propen-1-one for example; antiproliferative agent; tumor, cancer treatment INDENA S.P.A. (IT) 2002-10-31 — — US disclosed
CN-1371370-A Chalcone coumarins INDENA SPA (IT) 2002-09-25 — — CN disclosed
CN-1371370-A Chalcone coumarins INDENA SPA (IT) 2002-09-25 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020161036-A1 1-(4-methyl-7-(3-methylbut-2-enyloxy)coumarin-8-yl)-3-(pyridin e-3-yl)- propen-1-one for example; antiproliferative agent; tumor, cancer treatment NFKBIA, MKI67, HPD CYP1B1 2546/4885MAOB 4087/4885MAPT 4371/4885
US-11950594-B2 Methods and compositions for inhibiting formation of biofilms BLVRB, MLEC, CLPP CYP1B1 148/4885MAOB 232/4885MAPT 4425/4885
US-20220167614-A1 METHODS AND COMPOSITIONS FOR INHIBITING FORMATION OF BIOFILMS BLVRB, MLEC, CLPP CYP1B1 148/4885MAOB 232/4885MAPT 4425/4885
US-20130210909-A1 COUMARIN-CHALCONES AS ANTICANCER AGENTS HCCS, XPO5, CIAPIN1 CYP1B1 737/4885MAOB 4231/4885MAPT 3772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.